Losartan improves erectile dysfunction in diabetic patients: a clinical trial
To obtain Salama N, Kagawa S . Restoration of erectile capacity in normotensive aged rats by modulation of angiotensin receptor type 1.
According to the baseline of the IIEF-5 scores, each treatment group (tadalafil, losartan and tadalafil plus losartan) was divided into 3 sub-groups: mild (12<=IIEF-5<=21), moderate (8<=IIEF-5<=11) and severe (IIEF-5<=7) respectively. Department of Urology, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Urology, University of Texas Medical School at Houston and MD Anderson Cancer Center, Houston, TX, USAYou can also search for this author in We used the scores of IIEF-5 to divide the patients into three degrees: mild (12<=IIEF-5<=21), moderate (8<=IIEF-5<=11) and severe (IIEF-5<=7) respectively.Statistical Program for Social Sciences for Windows 17.0 statistics package program was used for statistical analysis of the data. Treatment strategies for diabetic patients suffering from erectile dysfunction. Sexual dysfunction in hypertensive patients treated with losartan. Marian Eure, RN, is a registered nurse with more than 25 years of experience in adult healthcare, health promotion, and health education. Renin–angiotensin system in rabbit corpus cavernosum: functional characterization of angiotensin II receptors. The Ang II levels of plasma and cavernous tissue in G2 group were both significantly increased compared to G1 group. The combination therapy of losartan and tadalafil appeared to be more effective than monotherapy.Chen Y, Dai Y, Wang R . The pathogenesis of diabetic ED is multifactorial, involving the neural, vascular, endocrine and metabolic systems.Our previous study showed that the angiotensin II (Ang II) level in the cavernosum of diabetic rats was much higher than that in normal controls.ARBs, a class of selective inhibitors of AT1, such as losartan, valsartan and irbesartan, are medications commonly used for cardiovascular disease. Beta-blockers (metoprolol, carvedilol, atenolol) and diuretics (HCTZ) negatively affect erectile function, while calcium channel blockers and ACE inhibitors seem to have neutral effects. The rates of erection and the ICP after electrostimulation for diabetic rats treated with valsartan were significantly higher than that in diabetic rats treated with normal saline and spironolactone. In the group of men with sexual dysfunction, 88 percent reported improvement in at least one area of sexual function and 73.7% reported an improved quality of life. Ureteral function is modulated by a local renin–angiotensin system. The body weight and serum glucose level of the rats was shown in The rates and frequency of erection of each group after hypodermic injection of apomorphine were reported in The erectile frequency of each group in the APO test. Valsartan treatment reverses erectile dysfunction in diabetic rats. Racine N, Hamet P, Sampalis JS, Longo N, Bastien N.J Hum Hypertens. Liau CS, Lee CM, Sheu SH, Ueng KC, Chien KL, Su TC Fusco F, Razzoli E, Imbimbo C, Rossi A, Verze P, Mirone V . Baseline characteristics for patients in each group are presented in The mean IIEF-5 scores were significantly improved with the treatment of tadalafil (9.40±3.66 vs 16.00±4.55) or losartan (9.68±3.46 vs 13.28±4.92) or losartan plus tadalafil (9.94±4.02 vs 18.61±4.83) (Mean IIEF-5 (International Index of Erectile Function) scores at baseline and endpoint of each group.
In the tadalafil, losartan and losartan plus tadalafil treatment groups, the percentages of positive answers to SEP-2 increased from 32.3 to 80.7% and 34.4 to 65.6% and 35.5 to 90.3% as compared with 33.3 to 40.0% in the control group (The percentage of positive answers to the sexual encounter profile questions-2 (SEP-2) in diabetic patients with erectile dysfunction (ED) at baseline and following 12 weeks of treatment. Please enable it to take advantage of the complete set of features! 2001;321(5):336-41. doi:10.1097/00000441-200105000-00006 Cleveland Clinic. Biochemistry and pharmacology of the renin–angiotensin system. Montorsi F, Verheyden B, Meuleman E, Jünemann KP, Moncada I, Valiquette L Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A Porst H, Glina S, Ralph D, Zeigler H, Wong DG, Woodward B .